Literature DB >> 23296251

Hepatitis C in 2012: On the fast track towards IFN-free therapy for hepatitis C?

Heiner Wedemeyer1.   

Abstract

Mesh：

Substances：

Year:  2013        PMID： 23296251     DOI： 10.1038/nrgastro.2012.247

Source DB:  PubMed          Journal:  Nat Rev Gastroenterol Hepatol        ISSN： 1759-5045            Impact factor:   46.802


× No keyword cloud information.
  9 in total

1.  The protease inhibitor, GS-9256, and non-nucleoside polymerase inhibitor tegobuvir alone, with ribavirin, or pegylated interferon plus ribavirin in hepatitis C.

Authors:  Stefan Zeuzem; Peter Buggisch; Kosh Agarwal; Patrick Marcellin; Daniel Sereni; Hartwig Klinker; Christophe Moreno; Jean-Pierre Zarski; Yves Horsmans; Hongmei Mo; Sarah Arterburn; Steven Knox; David Oldach; John G McHutchison; Michael P Manns; Graham R Foster
Journal:  Hepatology       Date:  2012-03       Impact factor: 17.425

2.  EASL Clinical Practice Guidelines: management of hepatitis C virus infection.

Authors: 
Journal:  J Hepatol       Date:  2011-03-01       Impact factor: 25.083

3.  New protease inhibitors and direct-acting antivirals for hepatitis C: interferon's long goodbye.

Authors:  Geoffrey Dusheiko; Heiner Wedemeyer
Journal:  Gut       Date:  2012-08-30       Impact factor: 23.059

4.  Dual therapy with the nonstructural protein 5A inhibitor, daclatasvir, and the nonstructural protein 3 protease inhibitor, asunaprevir, in hepatitis C virus genotype 1b-infected null responders.

Authors:  Kazuaki Chayama; Shoichi Takahashi; Joji Toyota; Yoshiyasu Karino; Kenji Ikeda; Hiroki Ishikawa; Hideaki Watanabe; Fiona McPhee; Eric Hughes; Hiromitsu Kumada
Journal:  Hepatology       Date:  2012-01-30       Impact factor: 17.425

5.  Cost-effectiveness of boceprevir or telaprevir for untreated patients with genotype 1 chronic hepatitis C.

Authors:  Calogero Cammà; Salvatore Petta; Marco Enea; Raffaele Bruno; Fabrizio Bronte; Vincenza Capursi; Americo Cicchetti; Giorgio L Colombo; Vito Di Marco; Antonio Gasbarrini; Antonio Craxì
Journal:  Hepatology       Date:  2012-07-12       Impact factor: 17.425

Review 6.  Treating viral hepatitis C: efficacy, side effects, and complications.

Authors:  M P Manns; H Wedemeyer; M Cornberg
Journal:  Gut       Date:  2006-09       Impact factor: 23.059

7.  Preliminary study of two antiviral agents for hepatitis C genotype 1.

Authors:  Anna S Lok; David F Gardiner; Eric Lawitz; Claudia Martorell; Gregory T Everson; Reem Ghalib; Robert Reindollar; Vinod Rustgi; Fiona McPhee; Megan Wind-Rotolo; Anna Persson; Kurt Zhu; Dessislava I Dimitrova; Timothy Eley; Tong Guo; Dennis M Grasela; Claudio Pasquinelli
Journal:  N Engl J Med       Date:  2012-01-19       Impact factor: 91.245

8.  Raloxifene hydrochloride is an adjuvant antiviral treatment of postmenopausal women with chronic hepatitis C: a randomized trial.

Authors:  Norihiro Furusyo; Eiichi Ogawa; Masayuki Sudoh; Masayuki Murata; Takeshi Ihara; Takeo Hayashi; Hiroaki Ikezaki; Satoshi Hiramine; Haru Mukae; Kazuhiro Toyoda; Hiroaki Taniai; Kyoko Okada; Mosaburo Kainuma; Eiji Kajiwara; Jun Hayashi
Journal:  J Hepatol       Date:  2012-08-10       Impact factor: 25.083

9.  Selective estrogen receptor modulators inhibit hepatitis C virus infection at multiple steps of the virus life cycle.

Authors:  Yuko Murakami; Masayoshi Fukasawa; Yukihiro Kaneko; Tetsuro Suzuki; Takaji Wakita; Hidesuke Fukazawa
Journal:  Microbes Infect       Date:  2012-10-23       Impact factor: 2.700
  9 in total
  2 in total

1.  Comprehensive phenotyping of regulatory T cells after liver transplantation.

Authors:  Anna Gronert Álvarez; Paraskevi Fytili; Pothakamuri V Suneetha; Anke R M Kraft; Christin Brauner; Jerome Schlue; Till Krech; Frank Lehner; Christoph Meyer-Heithuis; Elmar Jaeckel; Juergen Klempnauer; Michael P Manns; Markus Cornberg; Heiner Wedemeyer
Journal:  Liver Transpl       Date:  2015-01-20       Impact factor: 5.799

2.  The Range of Uncertainty: a Tool for Efficiently Addressing Result Variability Around Clinical Decision Points for Hepatitis C Response-guided Therapy.

Authors:  Paul Jülicher; Jens Dhein
Journal:  Biomark Insights       Date:  2014-04-09
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.